Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge – Phase II: Stage I

    NIH Challenges’ TRDNT Challenge – Phase II: Stage I supports the development and demonstration of novel RNA-targeting technologies aimed at advancing precision therapeutics for disease.

    OverviewSimilar Grants
    OverviewSimilar Grants

    Transformative Technologies for Experimental and Computational RNome Characterization and Functional Analysis

    This grant supports early-stage projects to develop innovative experimental and computational tools for comprehensive RNA analysis, aiming to overcome current limitations and advance research on RNA’s roles in health and disease.

    HHS-NIH11Forecasted Feb 15, 2027$500,000Forecasted

    Functional Target Validation for Alzheimer's Disease-Related Dementias

    This grant supports research to rigorously validate new therapeutic targets for Alzheimer's Disease-Related Dementias, aiming to accelerate treatment development through phased, milestone-driven projects.

    HHS-NIH11Forecasted Nov 6, 2026· 9d$1,800,000Forecasted

    RNomics Technology Enhancement Centers

    This grant will fund centers to advance and improve technologies for comprehensive analysis and mapping of all RNA molecules in cells and tissues, supporting broad research on RNA’s roles in health and disease.

    HHS-NIH11Forecasted Feb 1, 2027$2,000,000Forecasted

    Forecast for Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)

    This upcoming NIH grant will fund innovative preclinical research to develop new methods or agents that selectively target "undruggable" molecules involved in difficult-to-treat human diseases.

    HHS-NIH11Due Jan 18, 2027$275,000

    Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)

    Funding opportunity for advancing nanotechnology-based cancer treatments to improve effectiveness through innovative nanoparticle designs and cargos.

    HHS-NIH11Due Nov 16, 2026· 19d